These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1378 related items for PubMed ID: 33774736

  • 1. Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience.
    Bhatlapenumarthi V, Patwari A, Harb AJ.
    J Cancer Res Clin Oncol; 2021 Sep; 147(9):2789-2800. PubMed ID: 33774736
    [Abstract] [Full Text] [Related]

  • 2. Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis.
    Zhao Q, Zhang J, Xu L, Yang H, Liang N, Zhang L, Zhang F, Zhang X.
    Front Immunol; 2021 Sep; 12():730320. PubMed ID: 34646270
    [Abstract] [Full Text] [Related]

  • 3. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer.
    Allouchery M, Lombard T, Martin M, Rouby F, Sassier M, Bertin C, Atzenhoffer M, Miremont-Salame G, Perault-Pochat MC, Puyade M, French Network of Regional Pharmacovigilance Centers.
    J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428586
    [Abstract] [Full Text] [Related]

  • 4. Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody.
    Matsuoka H, Hayashi T, Takigami K, Imaizumi K, Shiroki R, Ohmiya N, Sugiura K, Kawada K, Sawaki A, Maeda K, Ando Y, Uyama I.
    BMC Cancer; 2020 Jul 14; 20(1):656. PubMed ID: 32664888
    [Abstract] [Full Text] [Related]

  • 5. Bone fracture as a novel immune-related adverse event with immune checkpoint inhibitors: Case series and large-scale pharmacovigilance analysis.
    Filippini DM, Gatti M, Di Martino V, Cavalieri S, Fusaroli M, Ardizzoni A, Raschi E, Licitra L.
    Int J Cancer; 2021 Aug 01; 149(3):675-683. PubMed ID: 33844854
    [Abstract] [Full Text] [Related]

  • 6. Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System.
    Raschi E, Mazzarella A, Antonazzo IC, Bendinelli N, Forcesi E, Tuccori M, Moretti U, Poluzzi E, De Ponti F.
    Target Oncol; 2019 Apr 01; 14(2):205-221. PubMed ID: 30927173
    [Abstract] [Full Text] [Related]

  • 7. Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events.
    Siddiqui BA, Gheeya JS, Goswamy R, Bathala TK, Surasi DS, Gao J, Shah A, Campbell MT, Msaouel P, Goswami S, Wang J, Zurita AJ, Jonasch E, Corn PG, Aparicio AM, Siefker-Radtke AO, Sharma P, Subudhi SK, Tannir N.
    J Immunother Cancer; 2021 Jul 01; 9(7):. PubMed ID: 34326169
    [Abstract] [Full Text] [Related]

  • 8. Delayed immune-related adverse events in long-responders of immunotherapy: a single-center experience.
    Kitano M, Honda T, Hikita E, Masuo M, Miyazaki Y, Kobayashi M.
    Asia Pac J Clin Oncol; 2024 Aug 01; 20(4):463-471. PubMed ID: 38608154
    [Abstract] [Full Text] [Related]

  • 9. Immune Checkpoint Inhibitor Rechallenge Safety and Efficacy in Stage IV Non-Small Cell Lung Cancer Patients After Immune-Related Adverse Events.
    Guo M, VanderWalde AM, Yu X, Vidal GA, Tian GG.
    Clin Lung Cancer; 2022 Dec 01; 23(8):686-693. PubMed ID: 36050243
    [Abstract] [Full Text] [Related]

  • 10. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S, Hakozaki T, Kitadai R, Hosomi Y.
    Thorac Cancer; 2020 Jul 01; 11(7):1927-1933. PubMed ID: 32421224
    [Abstract] [Full Text] [Related]

  • 11. Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis.
    Ngamphaiboon N, Ithimakin S, Siripoon T, Sintawichai N, Sriuranpong V.
    BMC Cancer; 2021 Nov 25; 21(1):1275. PubMed ID: 34823493
    [Abstract] [Full Text] [Related]

  • 12. Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients.
    Song P, Zhang D, Cui X, Zhang L.
    Thorac Cancer; 2020 Sep 25; 11(9):2406-2430. PubMed ID: 32643323
    [Abstract] [Full Text] [Related]

  • 13. Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States.
    Yang F, Shay C, Abousaud M, Tang C, Li Y, Qin Z, Saba NF, Teng Y.
    J Exp Clin Cancer Res; 2023 Jan 05; 42(1):4. PubMed ID: 36600271
    [Abstract] [Full Text] [Related]

  • 14. Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitors.
    Maillet D, Corbaux P, Stelmes JJ, Dalle S, Locatelli-Sanchez M, Perier-Muzet M, Duruisseaux M, Kiakouama-Maleka L, Freyer G, Boespflug A, Péron J.
    Eur J Cancer; 2020 Jun 05; 132():61-70. PubMed ID: 32334337
    [Abstract] [Full Text] [Related]

  • 15. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
    Zheng Y, Kim R, Yu T, Gayle JA, Wassel CL, Dreyfus J, Phatak H, George S.
    Oncologist; 2021 Nov 05; 26(11):e2002-e2012. PubMed ID: 34327774
    [Abstract] [Full Text] [Related]

  • 16. Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA.
    Kalinich M, Murphy W, Wongvibulsin S, Pahalyants V, Yu KH, Lu C, Wang F, Zubiri L, Naranbhai V, Gusev A, Kwatra SG, Reynolds KL, Semenov YR.
    J Immunother Cancer; 2021 Mar 05; 9(3):. PubMed ID: 33789879
    [Abstract] [Full Text] [Related]

  • 17. Immune-related adverse events associated with immune checkpoint inhibitors in patients with cancer.
    Sengul Samanci N, Cikman DI, Oruc K, Bedir S, Çelik E, Degerli E, Derin S, Demirelli FH, Özgüroğlu M.
    Tumori; 2021 Aug 05; 107(4):304-310. PubMed ID: 32935638
    [Abstract] [Full Text] [Related]

  • 18. Association Between Early Immune-related Adverse Events and Clinical Outcomes in Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
    Hosoya K, Fujimoto D, Morimoto T, Kumagai T, Tamiya A, Taniguchi Y, Yokoyama T, Ishida T, Hirano K, Matsumoto H, Kominami R, Tomii K, Suzuki H, Hirashima T, Uchida J, Morita M, Kanazu M, Sawa N, Makio T, Hara S, Tamiya M.
    Clin Lung Cancer; 2020 Jul 05; 21(4):e315-e328. PubMed ID: 32113737
    [Abstract] [Full Text] [Related]

  • 19. Real-world safety experience with immune checkpoint inhibitors in Saudi Arabia.
    Al Nuhait M, Bajnaid E, Al Otaibi A, Al Shammari A, Al Awlah Y.
    Sci Prog; 2021 Jul 05; 104(1):36850421997302. PubMed ID: 33689534
    [Abstract] [Full Text] [Related]

  • 20. Immune-related adverse events after immune checkpoint inhibitor exposure in adult cancer patients with pre-existing autoimmune diseases.
    Pizuorno Machado A, Shatila M, Liu C, Wang J, Altan M, Zhang HC, Thomas A, Wang Y.
    J Cancer Res Clin Oncol; 2023 Aug 05; 149(9):6341-6350. PubMed ID: 36752908
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 69.